Meningococcal carriage and immunity in western Burkina Faso, 2003

Vaccine

Volumn 25, Issue SUPPL. 1, 2007, Pages

  Yaro, Seydou ^a   Traoré, Yves ^b   Tarnagda, Zekiba ^c   Sangaré, Lassana ^d   NjanpopLafourcade, Berthe Marie ^e   Drabo, Aly ^a   Findlow, Helen ^f   Borrow, Raymond ^f   Nicolas, Pierre ^g   Gessner, Bradford D ^e   Mueller, Judith E ^e  

^a CENTRE MURAZ   (Burkina Faso)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^d CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^e Agence de Medecine Preventive   (France)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

Carriage; Immunity; Neisseria meningitidis

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANALYTIC METHOD; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BLOOD GROUP TYPING; BURKINA FASO; CHILD; CONTROLLED STUDY; EPIDEMIC MENINGITIS; HUMAN; MAJOR CLINICAL STUDY; NEISSERIA MENINGITIDIS; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BURKINA FASO; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP W-135;

EID: 34547650985     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.039     Document Type: Article

References (19)

1. Kwara A., Adegbola R.A., Corrah P.T., Weber M., Achtman M., Morelli G., et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop Med Int Health 3 9 (1998) 742-746
2. Taha M.K., Parent du Chatelet I., Schlumberger M., Sanou I., Djibo S., de Chabalier F., et al. Neisseria meningitidis serogroups S135 and A were equally prevalent among meningitis cases occurring at the end of 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 40 3 (2002) 1083-1084
3. Parent du Châtelet I., Traore Y., Gessner B.D., Antignac A., Naccro B., Njanpop-Lafourcade B.M., et al. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. Clin Infect Dis 40 1 (2005) 17-25
4. Mueller J.E., Yaro S., Traoré Y., Sangare L., Tarnagda Z., Njanpop-Lafourcade B.M., et al. Neisseria meningitidis serogroup W135 and A: carriage and immunity in Burkina Faso, 2003. J Infect Dis 193 6 (2006) 812-820
5. Maiden M.C.J., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95 6 (1998) 3140-3145
6. Lal G., Balmer P., Joseph H., Dawson M., and Borrow R. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol 11 2 (2004) 272-279
7. Maslanka S.E., Gheesling L.L., LiButti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 2 (1997) 156-167
8. Balmer P., and Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 3 1 (2004) 89-99
9. Andrews N., Borrow R., and Miller E. Validation of serological correlate of protection for meningococcal C conjugated vaccine using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol 10 5 (2003) 780-786
10. Blakebrough I.S., Greenwood B.M., Whittle H.C., Bradley A.K., and Gilles H.M. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a Northern Nigerian community. J Infect Dis 146 5 (1982) 626-637
11. Amir J., Louie L., and Granoff D.M. Naturally acquired immunity to Neisseria meningitidis group A. Vaccine 23 8 (2005) 977-983
12. Raghunathan P.L., Jones J.D., Tiendrebeogo S.R., Sanou I., Sangare L., Kouanda S., et al. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J Infect Dis 193 5 (2006) 607-616
13. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129 6 (1969) 1327-1348
14. Reller L.B., MacGregor R.R., and Beaty H.N. Bacterial antibody after colonization with Neisseria meningitidis. J Infect Dis 127 1 (1973) 56-62
15. Holten E., Vaage L., and Jyssum K. Bactericidal activity in sera from carriers of sulphonamide-resistant meningococci. Scand J Infect Dis 2 2 (1970) 201-204
16. MacLennan J.M., Urwin R., Obaro S., Griffiths D., Greenwood B., and Maiden M.C.J. Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy?. Lancet 356 9235 (2000) 1078
17. Maiden M.C.J., Stuart J.M., and The UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococc7al C conjugate polysaccharide vaccination. Lancet 359 9320 (2002) 1829-1830
18. Forgor A.A., Leimkugel J., Hodgson A., Bugri A., Dangy J.P., Gagneux S., et al. Emergence of W135 meningococcal meningitis in Ghana. Trop Med Intern Health 10 12 (2005) 1229-1234
19. World Health Organization. Meningococcal disease in the African Meningitis Belt, epidemic season 2006. Available at http://www.who.int/csr/don/2006_03_21/en/index.html. Accessed April 24, 2006.